Vaccines Europe

What Vaccines Europe does

Vaccines Europe is a specialized vaccines group within EFPIA (European Federation of Pharmaceutical Industries and Associations), headquartered in Belgium. It operates as a non-profit trade association representing 16 vaccine companies of all sizes that do business in Europe, including major global innovative manufacturers and small and medium-sized enterprises. The association's stated mission is to foster innovation and recognition of life-course immunisation in Europe, and it serves as the unified industry voice in EU policy and regulatory discussions.

Its core deliverables are policy advocacy and research intelligence rather than commercial products. The flagship outputs include the annual Pipeline Review documenting 91 vaccine candidates across 12 immunisation technology platforms (RNA, protein subunit, live-attenuated virus, whole-inactivated virus, glycoconjugate, virus-like particle, protein nanoparticles, monoclonal antibodies, toxoid, MAPS, Generalised Modules for Membrane Antigens, and multiple platforms) and 30+ disease areas; Vaccine Market Access Analysis covering EU27 and the United Kingdom; position papers on EU HTA Regulation, adult immunisation, and vaccine availability; and the EU Elections 2024 Mission advocating for an EU Immunisation Strategy. The organisation does not sell products to end customers and operates on a membership-funded basis within EFPIA.

The business model is association-based: Vaccines Europe does not generate licensing or product revenue but is funded through member company contributions channelled via EFPIA. Its value proposition rests on three functional pillars — facilitating industry-to-policymaker dialogue, generating evidence-based research on vaccine value and market access, and advocating for timely, consistent, and transparent vaccine assessment frameworks. Its primary stakeholders are vaccine manufacturers (members), EU institutions, national governments, public health agencies, NITAGs, and patient-facing public health organisations.

Name

Vaccines Europe

Legal name

Vaccines Europe

Website

https://vaccineseurope.eu

Company type

Private

Founded year

1991

Operating status

Operating

Headcount range

1–10 employees

Short description

Vaccines Europe is a non-profit trade association within EFPIA representing 16 vaccine companies operating in Europe, providing policy advocacy, annual pipeline reviews, and market access research to EU institutions and public health authorities.

Ownership category

akta.pro rank

Product category

Pharmaceutical Industry Association / Vaccine Industry Advocacy

NAICS

Professional Organizations (813920)

SIC

Services-Membership Organizations (8600)

akta.pro primary industry

Vaccine Policy, Advisory Committees & Program Governance (HLAJAHAJ)

akta.pro secondary industries

Immunization & Vaccination Programs Administration (BPAIAJAD), Vaccine Procurement, Tendering & Immunization Supply Programs (HLAIAEAN)

Keywords

• Vaccine industry advocacy
• Immunisation policy
• Vaccine market access
• Pharmaceutical trade association
• Life-course immunisation

Headquarters

HQ city

Brussels

HQ country

Belgium

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Membership-based association representation: Vaccines Europe operates as a specialised group within EFPIA, representing vaccine companies of all sizes operating in Europe. The association advocates for policy positions, conducts research, and provides industry representation services to its members.

Distribution channels1 record

Marketing channels7 records

Core offering

Vaccines Europe is a trade association that represents vaccine companies of all sizes operating in Europe, providing policy advocacy, industry research, and stakeholder engagement services to its members. Its core deliverables include the annual Pipeline Review of vaccine candidates in development, market access analyses, position papers on vaccine policy topics, and dialogue with EU institutions and national governments on regulatory, financing, and immunisation programme matters. The association does not sell commercial products but provides collective representation and intelligence services funded by member dues.

Product overview

Vaccines Europe is a specialised vaccines group within EFPIA (European Federation of Pharmaceutical Industries and Associations) that represents vaccine companies of all sizes operating in Europe. Rather than offering a commercial product, Vaccines Europe provides a suite of policy advocacy resources, research intelligence, and stakeholder engagement tools. Its core offerings include the annual Pipeline Review (documenting vaccine candidates across member companies), Vaccine Market Access Analysis (addressing pathways for vaccine inclusion in national immunisation programmes), and Position Papers on key vaccine policy topics. The organization also publishes research publications, runs policy initiatives such as the EU Elections 2024 Mission, and maintains a media hub with blogs, newsletters, and events for stakeholder engagement.

Differentiator

Problem solved

Functional benefit

Products and services

• Vaccines Europe Pipeline Review Annual research and intelligence report documenting vaccine candidates in development across Vaccines Europe's 16 member companies, covering 12 immunisation technology platforms, 30+ disease areas, and development phases. The review covers 86 prophylactic and 2 therapeutic vaccines plus 3 prophylactic monoclonal antibodies, intended for member companies, policymakers, and public health stakeholders.
• Vaccine Market Access Analysis Policy research and recommendations for improving vaccine market access pathways in the EU27 and the United Kingdom, analysing the time vaccines take to reach populations after authorisation and identifying barriers to timely access.
• Vaccine Assessment & Decision-Making Framework Policy framework built on four principles—timeliness, inclusiveness, consistency, and transparency—to enhance vaccine assessment and decision-making pathways across the European Union.
• Position Papers Formal policy positions on vaccine-related topics including EU HTA Regulation, availability, affordability and access of vaccines, and adult immunisation policy in Europe, published for policymakers and stakeholders.
• Publications & Reports Research publications including analyses of Vaccines Europe members' clinical pipelines and their role in global health security infrastructure, made available to members, policymakers, and the broader public health community.
• EU Elections 2024 Mission Advocacy initiative calling for an EU Immunisation Strategy during the 2024-2029 EU legislative period, focused on fostering innovation, life-course immunisation, and sustainable immunisation financing across Europe.

Quantifiable outcome

• 154 million lives saved through immunisation over 50 years globally
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• CEPI (Coalition for Epidemic Preparedness Innovations)coreStrategic or Co-development Partner · 4 December 2025Joint statement on investing in vaccine R&D to support EU and global health security and preparedness. Both organisations advocate for increased EU investment in vaccine innovation and preparedness through FP10 and MFF negotiations.
• IAVIcoreStrategic or Co-development Partner · 4 December 2025Joint statement calling for EU prioritisation of vaccine R&D and preparedness. IAVI is a non-profit scientific organisation focused on developing vaccines and antibodies for global health.
• PATHcoreStrategic or Co-development Partner · 4 December 2025Co-signatory of joint statement on vaccine R&D investment. PATH works to accelerate health equity through innovation in global health.
• DSW (Deutsche Stiftung Weltbevölkerung)minorStrategic or Co-development Partner · 4 December 2025Co-signatory of joint statement advocating for increased EU investment in vaccine R&D and health preparedness.
• European Parliament (MEPs)coreStrategic or Co-development Partner · 4 December 2025Members of European Parliament including Wouter Beke, Christophe Clergeau, Charles Goerens, Michael Hadjipantela, Romana Jerković, Tilly Metz, Leire Pajín, Oliver Schenk, and Aurelijus Veryga co-authored joint statement on vaccine R&D investment for EU health security.
• International Pandemic Preparedness Secretariat (IPPS)minorStrategic or Co-development Partner · 4 December 2025Supporting organisation for the joint statement on vaccine R&D investment and EU health security preparedness.
• EFPIA (European Federation of Pharmaceutical Industries and Associations)coreStrategic or Co-development PartnerVaccines Europe is a specialised vaccines group within EFPIA, representing vaccine companies operating in Europe. This structural relationship provides access to broader pharmaceutical industry advocacy networks and resources.
• EU InstitutionscoreStrategic or Co-development PartnerVaccines Europe engages with EU institutions to improve vaccine market access pathways, including work with EMA on regulatory frameworks and ECDC on immunisation policies.
• National Immunisation Technical Advisory Groups (NITAGs)coreStrategic or Co-development PartnerVaccines Europe advocates for strengthening NITAGs to improve vaccine assessment and decision-making across EU member states.

Scale indicators15 records

Recent moves5 records

Expansion highlights4 records

Emerging players

• European Vaccine Initiative (EVI): EVI is a non-profit R&D organisation supporting the development of vaccines for diseases of poverty and emerging infectious diseases. It complements Vaccines Europe's pipeline intelligence work with hands-on coordination of vaccine R&D consortia.
• EUCOPE (European Confederation of Pharmaceutical Entrepreneurs): EUCOPE represents small and mid-sized European pharmaceutical and biotech companies. It overlaps with Vaccines Europe's SME advocacy and competes for influence with EFPIA on EU policy issues affecting innovative medicine developers.

Direct peers

• BIO (Biotechnology Innovation Organization): BIO is the US biotechnology industry association that runs the BIO International Convention and advocates for vaccine and biologics innovation. It is the most direct US analogue to Vaccines Europe in scope and function.
• IFPMA (International Federation of Pharmaceutical Manufacturers and Associations): IFPMA is the global pharmaceutical industry association. It engages in the same type of vaccine and immunisation policy advocacy as Vaccines Europe, but at a global rather than European level, and represents the same multinational innovator members.
• PhRMA (Pharmaceutical Research and Manufacturers of America): PhRMA is the US pharmaceutical industry association. While it covers a broader therapeutic scope than Vaccines Europe, it conducts analogous advocacy, pipeline intelligence and policy research on behalf of its research-based members.

Others

• WHO Immunization, Vaccines and Biologicals (IVB) department: WHO IVB sets global immunisation policy (including the vaccines cited by Vaccines Europe in its 154M-lives-saved statistic). It is the public-sector counterpart that Vaccines Europe engages with as part of its market access and policy mission, not an industry peer but a closely linked stakeholder.
• Gavi, the Vaccine Alliance: Gavi is a public-private partnership that finances immunisation in lower-income countries. While its members include some of Vaccines Europe's constituent companies, Gavi is a procurement/allocation platform, not an industry association — an adjacent ecosystem actor.

Broad incumbents

• EFPIA: EFPIA is the parent federation of which Vaccines Europe is a specialised vaccines group. Both are European pharma industry associations engaged in policy advocacy and stakeholder engagement; Vaccines Europe operates as a focused sub-entity within EFPIA's broader portfolio.

Regional players

• ABPI (Association of the British Pharmaceutical Industry): ABPI is the UK pharmaceutical industry association. It mirrors Vaccines Europe's role in policy advocacy and market access analysis, but its geographic scope is the UK (one of Vaccines Europe's operating geographies).
• DCVMN (Developing Countries Vaccine Manufacturers Network): DCVMN represents vaccine manufacturers from developing countries. It is functionally analogous to Vaccines Europe but focused on emerging-market manufacturers, providing a global counterpart view on industry advocacy and capacity building.

Market position

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/vaccineseurope
• YouTubeyoutube.com/@vaccineseurope6892/videos
• LinkedInlinkedin.com/company/vaccines-europe

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vaccines Europe